title: Intravenous iron for the treatment of iron deficiency in IBD: the pendulum is swinging.
abstract: Intravenous (IV) iron therapy has been a major asset in the management of refractory iron-deficiency anemia in inflammatory bowel disease (IBD) and other diseases. However, the cost-effectiveness of parenteral substitution as the first-line treatment of this condition in IBD has been questioned. A study published by Reinisch et al. in this issue of the journal fails to show non-inferiority of iron isomaltose 1,000, a novel high-dose IV preparation, compared to oral iron sulfate.
authors.affiliation: Division of Gastroenterology, University of Leuven and University of Toronto, Leuven, Belgium.
authors.forename: Gert
authors.initials: G
authors.lastname: Van Assche
mesh_terms: D018798:Anemia, Iron-Deficiency / Q000188:drug therapy* / Q000209:etiology*; D004187:Disaccharides / Q000627:therapeutic use*; D005260:Female; D005290:Ferric Compounds / Q000627:therapeutic use*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications*; D007501:Iron / Q000627:therapeutic use*; D008297:Male
chemical_list: D004187:Disaccharides; D005290:Ferric Compounds; C557707:iron isomaltoside 1000; D007501:Iron